{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:31:08Z","timestamp":1785205868471,"version":"3.55.0"},"reference-count":85,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T00:00:00Z","timestamp":1294099200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There have been numerous research milestones since the discovery of the hepatitis B virus (HBV) in the 1960s. These mark major advances in the serology and epidemiology of HBV infection, in indentifying the wide clinical spectrum of acute and chronic hepatic diseases as well as the extrahepatic conditions induced by this virus, the molecular biology of the virus including its variants and mutants, its molecular diagnosis and monitoring, the host immune responses to the infecting virus, the pathogenesis and immunopathogenesis of liver disease as well as its natural course and outcome. These landmark discoveries are the firm background for current and future developments in treatment. There are three consecutive and partly overlapping chronological periods to treatment milestones beginning with recombinant standard interferon\u2010alpha (IFN\u2010\u03b1) in the 1980s, then oral antivirals from 1998 to the present and in 2005 pegylated IFN\u2010\u03b1 (PEG\u2010IFN). The renewed interest in PEG\u2010IFN\u2010\u03b1 treatment is now focused on both HBeAg\u2010positive and HBeAg\u2010negative chronic hepatitis B and it now also aims at HBsAg loss when associated with on\u2010treatment monitoring of serum HBV DNA and HBsAg levels, resulting in the closest thing to a cure of hepatitis B. The impressive progress made in all aspects of hepatitis B research suggests that curative therapy may be developed for all patients and for all phases of HBV infection in the foreseeable future. However for the moment, realistic efforts should be made to make treatment as widely available and affordable as possible and to apply current therapies to significantly reduce HBV morbidity and mortality.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2010.02406.x","type":"journal-article","created":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T15:16:48Z","timestamp":1294154208000},"page":"129-134","source":"Crossref","is-referenced-by-count":23,"title":["Milestones and perspectives in viral hepatitis B"],"prefix":"10.1111","volume":"31","author":[{"given":"Stephanos J.","family":"Hadziyannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1967.03120180053006"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03080070025007"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-66-5-924"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.207.10.1895"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196907172810302"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)90543-5"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/2181057a0"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(70)90926-8"},{"key":"e_1_2_8_10_2","first-page":"335","article-title":"A new antigen complex co\u2010occurring with Australia antigen","volume":"80","author":"Magnius LO","year":"1972","journal-title":"Acta Pathol Microbiol Scand B Microbiol Immunol"},{"key":"e_1_2_8_11_2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4049\/jimmunol.109.5.1017","article-title":"New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants","volume":"109","author":"Magnius LO","year":"1972","journal-title":"J Immunol"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra031087"},{"key":"e_1_2_8_13_2","first-page":"7","article-title":"Type B hepatitis","volume":"1","author":"Hoofnagle JH.","year":"1981","journal-title":"virology, serology and clinical course"},{"key":"e_1_2_8_14_2","first-page":"531","article-title":"Chronic hepatitis B","volume":"14","author":"Lai M","year":"2010","journal-title":"past, present, and future"},{"key":"e_1_2_8_15_2","first-page":"1828","article-title":"Management of hepatitis B","volume":"120","author":"Lok AS","year":"2001","journal-title":"2000\u2013summary of a workshop"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801644"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(70)91737-X"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/123.2.200"},{"key":"e_1_2_8_19_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0300-5089(21)00376-X","article-title":"Chronic viral hepatitis","volume":"3","author":"Hadziyannis SJ.","year":"1974","journal-title":"Clin Gastroenterol"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/inf.1975.7.issue-2.12"},{"key":"e_1_2_8_21_2","first-page":"423","article-title":"Hepatitis B virus infection and chronic liver disease in Taiwan","volume":"25","author":"Chen DS","year":"1978","journal-title":"Acta Hepatogastroenterol"},{"key":"e_1_2_8_22_2","first-page":"40","article-title":"Hepatocellular carcinoma and the hepatitis B virus","volume":"24","author":"Szmuness W.","year":"1978","journal-title":"evidence for a causal association"},{"key":"e_1_2_8_23_2","first-page":"55","article-title":"OMGE \u2013 Study on prevalence of hepatitis B surface antigen in different liver diseases","volume":"56","author":"Wewalka F","year":"1979","journal-title":"Scand J Gastroenterol"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-5089(21)00709-4"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90585-7"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198110293051807"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-9-200111060-00006"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50352"},{"key":"e_1_2_8_29_2","first-page":"S173","article-title":"Natural history of chronic hepatitis B virus infection","volume":"43","author":"Yim HJ","year":"2006","journal-title":"what we knew in 1981 and what we know in 2005"},{"key":"e_1_2_8_30_2","first-page":"1056","article-title":"Management of hepatitis B","volume":"45","author":"Hoofnagle JH","year":"2007","journal-title":"summary of a clinical research workshop"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60207-5"},{"key":"e_1_2_8_32_2","first-page":"200","article-title":"Mortality related to chronic hepatitis B and chronic hepatitis C in France","volume":"48","author":"Marcellin P","year":"2008","journal-title":"evidence for the role of HIV coinfection and alcohol consumption"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)91883-6"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1970.tb01550.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(72)91153-1"},{"key":"e_1_2_8_36_2","first-page":"327","article-title":"Cytoplasmic hepatitis B antigen in \u2018ground\u2010glass\u2019 hepatocytes of carriers","volume":"96","author":"Hadziyannis S","year":"1973","journal-title":"Arch Pathol"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(76)80456-8"},{"key":"e_1_2_8_38_2","first-page":"371","article-title":"Immunopathology of hepatitis B","volume":"6","author":"Bianchi L","year":"1979","journal-title":"Prog Liver Dis"},{"key":"e_1_2_8_39_2","first-page":"15","article-title":"Hepatitis B core antigen immune complexes in the liver of hepatitis B patients","volume":"37","author":"Ray MB","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5712-4_12"},{"key":"e_1_2_8_41_2","first-page":"1443","article-title":"Intrahepatic expression of HBcAg in chronic HBV hepatitis","volume":"12","author":"Chu CM","year":"1990","journal-title":"lessons from molecular biology"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)90811-E"},{"key":"e_1_2_8_43_2","first-page":"93","article-title":"[Genetic engineering and the hepatitis B virus]","volume":"5","author":"Brechot C","year":"1981","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_8_44_2","first-page":"293","article-title":"Structure and expression of the hepatitis B virus genome","volume":"50","author":"Wain\u2010Hobson S","year":"1981","journal-title":"Dev Biol Stand"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.me.35.020184.001251"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.17.6608"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02919083"},{"key":"e_1_2_8_48_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/oxfordjournals.bmb.a072402","article-title":"Molecular biology of hepadnavirus replication","volume":"46","author":"Pugh JC","year":"1990","journal-title":"Br Med Bull"},{"key":"e_1_2_8_49_2","first-page":"93","article-title":"Immune response to hepatitis B virus proteins","volume":"11","author":"Milich DR.","year":"1991","journal-title":"relevance of the murine model"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1159\/000150411"},{"key":"e_1_2_8_51_2","first-page":"405","article-title":"Virologic monitoring of hepatitis B virus therapy in clinical trials and practice","volume":"134","author":"Pawlotsky JM","year":"2008","journal-title":"recommendations for a standardized approach"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(86)80117-9"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-6-744"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(86)80120-9"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.1982.0114"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(86)80121-0"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840030505"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.11.1283"},{"key":"e_1_2_8_59_2","first-page":"130","article-title":"Hepatitis B e antigen\u2010negative chronic hepatitis B","volume":"26","author":"Hadziyannis SJ","year":"2006","journal-title":"natural history and treatment"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(86)90395-1"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100213"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90713-7"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90903-P"},{"key":"e_1_2_8_64_2","first-page":"7","article-title":"Hepatitis B e antigen negative chronic hepatitis B","volume":"1","author":"Hadziyannis SJ.","year":"1995","journal-title":"from clinical recognition to pathogenesis and treatment"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50148"},{"key":"e_1_2_8_66_2","unstructured":"HadziyannisSJ.Anti\u2010HBe positive chronic active hepatitis 1981;683. In:SzmunessW AlterH MaynardJ eds.Viral Hepatitis Symposium.New York: The Franklin Institute Press."},{"key":"e_1_2_8_67_2","first-page":"227","article-title":"EASL Clinical Practice Guidelines","volume":"50","author":"European Association for the Study of the Liver.","year":"2009","journal-title":"management of chronic hepatitis B"},{"key":"e_1_2_8_68_2","unstructured":"LokASF McmahonBJ.AASLD practice guidelines. Chronic hepatitis B: update 2009. Available athttp:\/\/www.aasld.org(accessed 9 August 2010)."},{"key":"e_1_2_8_69_2","first-page":"42","article-title":"Treatment of chronic anti\u2010HBe\u2010positive hepatitis B with interferon\u2010alpha","volume":"22","author":"Brunetto MR","year":"1995","journal-title":"J Hepatol"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-4-199308150-00011"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411702"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290321"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22956"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.25524"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043470"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040431"},{"key":"e_1_2_8_77_2","first-page":"73","article-title":"Prediction of treatment\u2010related HBsAg loss in HBeAG\u2010negative chronic hepatitis B","volume":"12","author":"Manesis EK","year":"2007","journal-title":"a clue from serum HBsAg levels"},{"key":"e_1_2_8_78_2","first-page":"1141","article-title":"Hepatitis B virus surface antigen levels","volume":"49","author":"Brunetto MR","year":"2009","journal-title":"a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B"},{"key":"e_1_2_8_79_2","first-page":"123","article-title":"Pegylated interferon alfa\u20102b alone or in combination with lamivudine for HBeAg\u2010positive chronic hepatitis B","volume":"365","author":"Janssen HL","year":"2005","journal-title":"a randomised trial"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.03.006"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.05.031"},{"key":"e_1_2_8_82_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.061"},{"key":"e_1_2_8_83_2","first-page":"355","article-title":"Characteristics of patients with chronic hepatitis B in France","volume":"45","author":"Zarski JP","year":"2006","journal-title":"predominant frequency of HBe antigen negative cases"},{"key":"e_1_2_8_84_2","first-page":"1151","article-title":"Early serum HBsAg drop","volume":"49","author":"Moucari R","year":"2009","journal-title":"a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients"},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21778"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(09)60020-9"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2010.02406.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2010.02406.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T07:55:53Z","timestamp":1694591753000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2010.02406.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":85,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1478-3231.2010.02406.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02406.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}